TORRANCE, Calif., Dec. 19, 2012 /PRNewswire/ -- Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced that Peter Ludlum, the company’s executive vice president and CFO, will give an overview of the company’s Phase 3 sickle cell disease trial and discuss recent developments with its regenerative medicine research at the 6th Annual OneMedForum on January 8, 2013 at 9:50 a.m. P.T. at the Sir Francis Drake Hotel in San Francisco. Additionally, Yutaka Niihara, M.D., MPH, president and CEO, and Willis Lee, chief operating officer, will join Ludlum for one-on-one meetings throughout the day.
About Emmaus Medical, Inc.
Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase 3 clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine products. For more information, please visit www.emmausmedical.com and www.nutrestore.com.
Contacts:
Media:
IQ-PR, Inc.
Lori Teranishi
415-981-1964
lteranishi@iqprinc.com
Investors:
PondelWilkinson
Matt Sheldon
310-279-5980
msheldon@pondel.com
SOURCE Emmaus Medical, Inc.
